![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Emergence of HIV-1 Drug Resistance Through Week 48 in the Global Women's WAVES Study:
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs. Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF
|
|
|
Reported by Jules Levin
ID Week 2016 Oct 26-30 New Orleans  
R Kulkarni1, SL Hodder2, H Cao1, S Chang1, MD Miller1, KL White1
1Gilead Sciences, Inc., Foster City, CA, USA; 2West Virginia University, Morgantown, PA, USA
![HIV1](../images/110416/110416-3/HIV1.gif)
![HIV2](../images/110416/110416-3/HIV2.gif)
![HIV3](../images/110416/110416-3/HIV3.gif)
![HIV4](../images/110416/110416-3/HIV4.gif)
![HIV5](../images/110416/110416-3/HIV5.gif)
![HIV6](../images/110416/110416-3/HIV6.gif)
![HIV7](../images/110416/110416-3/HIV7.gif)
![HIV8](../images/110416/110416-3/HIV8.gif)
![HIV9](../images/110416/110416-3/HIV9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|